Human Microbiome Market

Human Microbiome Market, By Product Type [Food (Probiotics, Prebiotics, Medical Food Supplements, Others (Symbiotic, Antibiotics, etc.)), Microbome Drugs, Fecal Microbiota Transplant], By Application [Therapeutics, Diagnostics, Nutrition and Deities, Others (Cosmetics, Animal health etc.)], By Disease Indication (Auto Immune Disorder, Clostridium Difficile Infection, Metabolic Disorder, Inflammatory Bowel disorder, Infectious Diseases, and Others (Cancer, Rare Diseases), By Distribution Channel (Hospital, Retail Pharmacies, and Online Pharmacies), and By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Human microbiome are the full range of microorganisms that are present inside and outside the Humans, It is collection of microbial genomes that contribute to metagenome, of a human. The human micro biota consists of the 10-100 trillion symbiotic microbial cells primarily bacteria in the gut the human. The age, nutrition, lifestyle, hormonal changes, inherited genes, and underlying disease are major determinants of the human microbiome, and any change or in balance in microbiota can cause life threatening illness such as cancer, bowel inflammatory disease, cardiovascular disease, and difficult-to-treat bacterial infections due to antibiotic resistance. Their roles ranges from enabling easy digestion of food, regulation of immune system, and production of vitamins such as Vitamin K, Vitamin B, and Vitamin B12. According to the article published published by journal of microbial biotechnology, published on August 2022, tissue immune responses are regulated by their microbiome composition, and each tissue has their specific microenvironment that makes their microbiome composition different, particularly in the context of different types of cancer, such as breast, colorectal, kidney, lung, and skin. Herein, key players in the microbiome industry are focusing on researches and studies.

Market Dynamics

The key players in the microbiome industry are focusing on researches and development of new molecular technologies such as metagenomics, transcriptomics. Recent advances in malnutrition research and infectious disease have established the potential for microbiome-based strategies to address the biggest challenges in global health including cancer, chronic inflammation in GIT, CVD, anxiety and depression, and others. For instance, in April 2023, Seres Therapeutics, a microbiome therapeutics company that developsbiological drugs, received the U.S. food and Drug Administration approval for it’s first orally administered microbiome therapeutic drug named ‘VOWSTT’ for prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI. Thus, the ongoing research and development in the field of human microbiome offer opportunities for the pharmaceutical companies to develop more innovative drugs or therapies that are involved to treat various range of rare diseases.

Key features of the study:

• This report provides an in-depth analysis of the global human microbiomes market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global human microbiomes market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Seres Therapeutics, BIOMESENSE, Microbiotica, Vedanta Biosciences, Inc., SECOND Seres Therapeutics, Biomesense, Microbiotica, Infant Bacterial Therapeutics AB, Vedanta Biosciences, Inc., Second genome therapeutics, 4D Pharma Ferring Inc, Enterome, BiomX, MaaT Pharma, Azitra, Illumina, Inc, Locus Biosciences, Inc, Finch Therapeutics Group, Inc, Rebiotix Inc, Servatus Ltd, Microbiome Research Pvt. Ltd, AOBiome, Axial Therapeutics, Inc, Biomica
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global human microbiomes market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human microbiomes market

Detailed Segmentation:

• Global Human Microbiomes Market, By Product Type:
• Food

Probiotics

Prebiotics

Medical Food Supplements

• Microbiome Drugs
• Fecal Microbiota Transplant
• Others (Symbiotic, Antibiotics, etc.)
• Global Human Microbiome Market, By Application:
• Therapeutics
• Diagnostics
• Nutrition and Deities
• Others (Cosmetics, Animal health etc. )
• Global Human Microbiome Market, By Disease Indication:
• Auto Immune Disorder

Clostridium Difficile Infection

Metabolic Disorder

Inflammatory Bowel disorder

• Infectious Diseases
• Others (Cancer, Rare Diseases)
• Global Human Microbiome Market, By Disribution Channel:
• Hospital
• Retail Pharmacies
• Online Pharmacies
• Global Human Microbiome Market, By Region:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa
• Company Profiles
• Seres Therapeutics
• Biomesense
• Microbiotica
• Infant Bacterial Therapeutics AB
• Vedanta Biosciences, Inc.
• SECOND GENOME THERAPEUTICS
• Finch Therapeutics Group, Inc
• Enterome
• BiomX
• MaaT Pharma
• Azitra
• Illumina, Inc
• Locus Biosciences, Inc
• Finch Therapeutics Group, Inc
• Rebiotix Inc
• Servatus Ltd
• Microbiome Research Pvt. Ltd
• AOBiome
• Axial Therapeutics, Inc
• Biomica